Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health
November 16, 2022 — Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.

Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens
October 27, 2022 — As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against history’s oldest pandemic.

Treatment Action Group Statement: U.S. District Court Ruling Allowing Employers to Deny PrEP Coverage Is a Dangerous Attack on Public Health
October 6, 2022 — Treatment Action Group (TAG)  unequivocally condemns the September 2022 U.S. District Court ruling in Fort Worth, Texas on the case Braidwood Management Inc. et al., v. Xavier Becerra et al., which ruled that the Affordable Care Act’s requirement that employers cover pre-exposure prophylaxis (PrEP) for HIV prevention was unconstitutional.

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
September 21, 2022 — As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of…

Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci
August 23, 2022 — Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.

Ten Principles for Access to Multi-disease Molecular Diagnostics: A Global Call to Action
August 23, 2022 — Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign are pleased to launch the Principles for Access to Multi-disease Molecular Diagnostics.

Treatment Action Group Adds Three New Board Members
August 23, 2022 — As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
August 1, 2022 — We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available
August 1, 2022 — Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.

1 / 4 / 6 x 24 Campaign Launched to Rally Energy, Political Will, Funding Needed to Fight Tuberculosis
July 31, 2022 — Against the backdrop of the COVID-19 pandemic and other concurrent global health, economic, social, and political crises, the 1 / 4 / 6 x 24 Campaign, launched during the AIDS conference in Montreal, seeks to improve TB treatment and prevention worldwide based on the latest medical innovations and to reignite…